Skip to main content
CancerDendritic CellsImmunotherapyVaccines

Ep. 52: “Lymphoma Immunotherapy” Featuring Dr. Joshua Brody

By April 25, 2023No Comments

Joshua Brody


Dr. Joshua Brody is the Director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai. The Brody lab studies basic and applied tumor immunology for the development of cancer immunotherapies, particularly for lymphomas and melanomas. He talks about dendritic cells to improve oncolytic virus immunotherapy and in situ vaccination to improve PD-1 blockade responses.

Featured Products and Resources:

The Immunology Science Round Up

Enhancing T Cell Immunity to SARS-CoV-2 Variants – A new mRNA vaccine component elicits non-spike T cell responses in mice while maintaining spike immunity.

Why Infants Are Protected from Pneumonia – Enhanced opsonophagocytosis by neonatal neutrophils improves protection against Streptococcus pneumoniae in early life.

Tertiary Lymphoid Structures and Lung Cancer Immunotherapy – Researchers identified endogenous retrovirus envelope glycoproteins as a dominant antitumor antibody target in lung cancer.

Engineered Bacteria As a Melanoma Vaccine – Scientists engineered a Staphylococcus epidermidis strain to express melanoma tumor antigens and tested their ability to drive antitumor immune responses.

Image courtesy of Dr. Joshua Brody

Subscribe to our newsletter!

Never miss updates about new episodes.